MedPath
Found 10 clinical trials|View Analysis
Sort by:

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Phase 3
Recruiting
Conditions
Obesity
Interventions
Drug: Tirzepatide
Drug: Retatrutide
First Posted Date
2024-10-28
Last Posted Date
2024-12-27
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
800
Registration Number
NCT06662383
Locations
🇺🇸

Albany Medical College, Division of Community Endocrinology, Albany, New York, United States

🇺🇸

Medical Advancement Centers of Arizona, Tempe, Arizona, United States

🇺🇸

Mary & Dick Allen Diabetes Center, Newport Beach, California, United States

and more 62 locations

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Phase 3
Recruiting
Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Interventions
Drug: Placebo
Drug: Retatrutide
First Posted Date
2024-04-25
Last Posted Date
2025-01-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
10000
Registration Number
NCT06383390
Locations
🇺🇸

Circle Clinical Research, Sioux Falls, South Dakota, United States

🇺🇸

Care Access - Memphis, Memphis, Tennessee, United States

🇺🇸

IMA Clinical Research Austin, Austin, Texas, United States

and more 718 locations

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Phase 3
Recruiting
Conditions
Diabetes Type 2
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2024-04-09
Last Posted Date
2025-01-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
480
Registration Number
NCT06354660
Locations
🇺🇸

Scottsdale Clinical Trials, Scottsdale, Arizona, United States

🇺🇸

Tucson Clinical Research Institute, Tucson, Arizona, United States

🇺🇸

San Fernando Valley Health Institute, Canoga Park, California, United States

and more 44 locations

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Phase 3
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2024-03-07
Last Posted Date
2025-01-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
320
Registration Number
NCT06297603
Locations
🇺🇸

Kidney & Hypertension Center - Apple Valley, Apple Valley, California, United States

🇺🇸

Hope Clinical Research, Inc., Canoga Park, California, United States

🇦🇷

Instituto Médico Catamarca IMEC, Rosario, Santa Fe, Argentina

and more 72 locations

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Phase 3
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Retatrutide
Drug: Semaglutide
First Posted Date
2024-02-15
Last Posted Date
2025-01-01
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1250
Registration Number
NCT06260722
Locations
🇨🇦

Dr. Steven V. Zizzo Research Professional Corporation, Hamilton, Ontario, Canada

🇨🇦

The Wharton Medical Clinic Clinical Trials Inc, Hamilton, Ontario, Canada

🇺🇸

University of Alabama - Department of Nutrition Sciences, Birmingham, Alabama, United States

and more 75 locations

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Phase 2
Recruiting
Conditions
Overweight or Obesity
Type 2 Diabetes
CKD
Interventions
Drug: Placebo
Drug: Retatrutide
First Posted Date
2023-07-07
Last Posted Date
2024-12-30
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
120
Registration Number
NCT05936151
Locations
🇬🇧

Futuremeds-Newcastle, Newcastle, England, United Kingdom

🇺🇸

The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States

🇺🇸

Care Access - 801 South Power Road, Mesa, Mesa, Arizona, United States

and more 38 locations

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Phase 3
Active, not recruiting
Conditions
Obesity
Overweight
Osteo Arthritis Knee
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2023-07-05
Last Posted Date
2024-12-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
405
Registration Number
NCT05931367
Locations
🇲🇽

IMED Internal Medicine Clin Trials, Monterrey, Nuevo León, Mexico

🇺🇸

Northwestern University, Chicago, Illinois, United States

🇨🇦

Wharton Medical Clinic, Hamilton, Ontario, Canada

and more 44 locations

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Phase 3
Active, not recruiting
Conditions
Obesity
Overweight
Osteoarthritis, Knee
Obstructive Sleep Apnea
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2023-07-03
Last Posted Date
2024-12-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
2300
Registration Number
NCT05929066
Locations
🇭🇺

Regia Med Kft, Szekesfehervar, Fejér, Hungary

🇲🇽

Kohler and Milstein Research S.A. de C.V., Mérida, Yucatán, Mexico

🇲🇽

Centro de Atención e Investigación Clínica, Aguascalientes, Mexico

and more 130 locations

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Phase 3
Active, not recruiting
Conditions
Obstructive Sleep Apnea
Overweight
Obesity
Type 2 Diabetes
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2023-07-03
Last Posted Date
2024-12-11
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1000
Registration Number
NCT05929079
Locations
🇲🇽

Kohler & Milstein Research S.A. De C.V., Mérida, Yucatán, Mexico

🇺🇸

Pinnacle Research Group, LLC, Anniston, Alabama, United States

🇺🇸

Cullman Clinical Trials, Cullman, Alabama, United States

and more 96 locations

A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Phase 3
Active, not recruiting
Conditions
Obesity
Cardiovascular Diseases
Interventions
Drug: Retatrutide
Drug: Placebo
First Posted Date
2023-05-31
Last Posted Date
2024-12-09
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1800
Registration Number
NCT05882045
Locations
🇦🇺

Camden Hospital, Camden, New South Wales, Australia

🇨🇦

Joanne F. Liutkus Medicine Professional Corporation, Cambridge, Ontario, Canada

🇸🇰

Human Care s.r.o., Kosice, Košický Kraj, Slovakia

and more 162 locations
© Copyright 2025. All Rights Reserved by MedPath